Daiichi Sankyo, Merck
Daiichi Sankyo, Merck Phase 3 Lung-Cancer Study Meets Primary Endpoint
Merck & Co. and Daiichi Sankyo on Tuesday said one of the drug candidates in their multibillion-dollar collaboration has hit its main goal in a late-stage lung-cancer study. Merck and Daiichi Sankyo said a Phase 3 study evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who received prior EGFR tyrosine kinase inhibitor treatment met its primary endpoint of progression-free survival.
An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...
A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids
STAT's podcast The Readout Loud discusses Summit's cancer immunotherapy, the company's co-CEO, Moderna's spending cuts and ...
Summit Therapeutics said its Ivonescimab treatment reduced the risk of disease progression or death by 49% compared with the ...
Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...
A U.S. appeals court has reinstated more than 500 lawsuits against drugmaker Merck & Co. because of its osteoporosis drug Fosamax, which plaintiffs allege increases risk of thigh bone fractures, ...
Merck ( MRK 0.53%) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...
Zacks.com on MSN4d
Merck Loses Around $32B in 3 Months: Time to Sell the Stock?Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...
A letter from the FDA rejecting Merck Sharpe & Dohme Corp.'s proposed label warning that its osteoporosis drug Fosamax could cause stress fractures doesn’t preempt state law claims alleging the ...
Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to ...
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback